A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life

ASRS is designed to evaluate for severity of symptoms as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). ASRS is composed of 18 questions, and uses a scale that ranges from 0-4 based on the individuals mark in either the "never, rarely, sometimes, often, very often" column for a possible total score of 72. The minimum score to qualify for study inclusion is 8 (i.e. 4 or more "symptom-positive" answers), and the maximum possible score is 72. The higher the score, the more indicative of higher severity of ADHD symptoms. Each column is used to describe the severity of the individuals symptoms based on the questions asked. Each participant is asked to make a mark within one column for each question that best describes their answer. Percentage of participants with confirmed diagnosis of ADHD in participants with psychiatric disorder based on adult ASRS will be reported.

DIVA 5.0 is a structured diagnostic interview for Adult ADHD, and is based on the criteria for ADHD in DSM-5. Whenever possible the DIVA should be completed with adults in the presence of a partner and/or family member, to enable retrospective and collateral information to be ascertained at the same time. The DIVA usually takes around one and a half hours to complete. The DIVA only asks about the core symptoms of ADHD required to make the DSM-IV diagnosis of ADHD, and does not ask about other co-occurring psychiatric symptoms, syndromes or disorders. In this study, participant will be interviewed using DIVA only if scores in ASRS showed positive diagnosis of ADHD.

Percentage of participants with confirmed diagnosis of ADHD in participants with psychiatric disorder based on DIVA 5.0 will be reported.

DSM-5 confirm the diagnosis of ADHD if meeting all of the following criteria: (i) having five out of nine ADHD inattention and/or hyperactivity/impulsivity symptoms for the last 6 months or more; (ii) having several symptoms before the 12 years of age; (iii) having several symptoms in at least two settings (e.g., at home or work; and with friends or family members); (iv) having symptoms interfering with quality of social, academic, or occupational functioning; and (v) having symptoms that do not occur exclusively during the course of a psychotic disorder and are not better explained by another mental disorder.

Percentage of participants with confirmed diagnosis of ADHD in participants with psychiatric disorder based on DSM-5 will be reported.

Number of modalities for non-ADHD psychiatric/psychological clinical management will be assessed.

Type of treatment given to participants with ADHD for non-ADHD psychiatric/psychological clinical management will be assessed.

Duration of treatment for non-ADHD psychiatric/psychological clinical management will be assessed.

Number of modalities for ADHD-specific psychiatric/psychological clinical management will be assessed.

Type of treatment given to participants with ADHD for ADHD-specific overall psychiatric/psychological clinical management will be assessed.

Duration of treatment for ADHD-specific psychiatric/psychological clinical management will be assessed.

FAST is a brief instrument designed to assess the main functioning problems experienced by psychiatric participants, particularly bipolar participants. It comprises 24 items that assess impairment or disability in six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time. The scale used to evaluate functionality is the FAST Scale, the minimum value being 0 and maximum value of 72, domain scores are scaled in a negative direction (i.e. lower scores denote higher functionality).

CGI-S is a 7-point scale to rate the participant's severity of illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis by means of one question: Considering your total clinical experience with this particular population, how mentally ill is the participant at this time which is rated on the following seven-point scale with range from 1 to 7 were: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants.

CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention: Compared to the participant's condition at admission to the project [prior to medication initiation], this participant's condition ranges from 1 to 7 were: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.

Utilization of health resources by the study population during the 12 months prior ADHD assessment in the total sample and according to the diagnosis will be assessed at baseline, 3-months and 9 months follow up.

Continues variables (e.g., age, functionality scores, quality of life scores, number of previous visits to the hospital) and categorical variables (e.g., sex, clinical characteristics, psychiatric disorders, ADHD warning signs, treatments, previous tests) will be described in the total sample and according to confirmed/no confirmed ADHD; and will be compared using T-test or ANOVA test (continues variables) and Chi squared test (categorical variables).